keyword
MENU ▼
Read by QxMD icon Read
search

DOTA

keyword
https://www.readbyqxmd.com/read/28533656/68ga-dota-d-phe1-tyr3-octreotide-dotatoc-pet-ct-in-a-suspected-case-of-recurrent-meningioma
#1
Sachin Jain, Ashwani Gupta, Anurag Jain
No abstract text is available yet for this article.
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28530267/lanthanide-based-peptide-biosensor-to-monitor-cdk4-cyclin-d-kinase-activity
#2
Juan A González-Vera, David Bouzada, Céline Bouclier, M Eugenio Vázquez, May C Morris
We describe a lanthanide biosensor that responds to CDK4 kinase activity in melanoma cell extracts through a significant and dose dependent increase in luminescence, thanks to sensitization of a DOTA[Tb(3+)] complex incorporated into a CDK4 substrate peptide by a unique tryptophan residue in an adjacent phosphoaminoacid binding moiety.
May 22, 2017: Chemical Communications: Chem Comm
https://www.readbyqxmd.com/read/28529632/imaging-of-chemokine-receptor-4-expression-in-neuroendocrine-tumors-a-triple-tracer-comparative-approach
#3
Rudolf A Werner, Alexander Weich, Takahiro Higuchi, Jan S Schmid, Andreas Schirbel, Michael Lassmann, Vanessa Wild, Martina Rudelius, Theodor Kudlich, Ken Herrmann, Michael Scheurlen, Andreas K Buck, Saskia Kropf, Hans-Jürgen Wester, Constantin Lapa
C-X-C motif chemokine receptor 4 (CXCR4) and somatostatin receptors (SSTR) are overexpressed in gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). In this study, we aimed to elucidate the feasibility of non-invasive CXCR4 positron emission tomography/computed tomography (PET/CT) imaging in GEP-NET patients using [(68)Ga]Pentixafor in comparison to (68)Ga-DOTA-D-Phe-Tyr3-octreotide ([(68)Ga]DOTATOC) and (18)F-fluorodeoxyglucose ([(18)F]FDG). Twelve patients with histologically proven GEP-NET (3xG1, 4xG2, 5xG3) underwent [(68)Ga]DOTATOC, [(18)F]FDG, and [(68)Ga]Pentixafor PET/CT for staging and planning of the therapeutic management...
2017: Theranostics
https://www.readbyqxmd.com/read/28526764/subarachnoid-hemorrhage-severely-impairs-brain-parenchymal-cerebrospinal-fluid-circulation-in-nonhuman-primate
#4
Romain Goulay, Julien Flament, Maxime Gauberti, Michael Naveau, Nolwenn Pasquet, Clement Gakuba, Evelyne Emery, Philippe Hantraye, Denis Vivien, Romina Aron-Badin, Thomas Gaberel
BACKGROUND AND PURPOSE: Subarachnoid hemorrhage (SAH) is a devastating form of stroke with neurological outcomes dependent on the occurrence of delayed cerebral ischemia. It has been shown in rodents that some of the mechanisms leading to delayed cerebral ischemia are related to a decreased circulation of the cerebrospinal fluid (CSF) within the brain parenchyma. Here, we evaluated the cerebral circulation of the CSF in a nonhuman primate in physiological condition and after SAH. METHODS: We first evaluated in physiological condition the circulation of the brain CSF in Macaca facicularis, using magnetic resonance imaging of the temporal DOTA-Gd distribution after its injection into the CSF...
May 19, 2017: Stroke; a Journal of Cerebral Circulation
https://www.readbyqxmd.com/read/28524118/novel-radiolabeled-bisphosphonates-for-pet-diagnosis-and-endoradiotherapy-of-bone-metastases
#5
REVIEW
Nina Pfannkuchen, Marian Meckel, Ralf Bergmann, Michael Bachmann, Chandrasekhar Bal, Mike Sathekge, Wolfgang Mohnike, Richard P Baum, Frank Rösch
Bone metastases, often a consequence of breast, prostate, and lung carcinomas, are characterized by an increased bone turnover, which can be visualized by positron emission tomography (PET), as well as single-photon emission computed tomography (SPECT). Bisphosphonate complexes of (99m)Tc are predominantly used as SPECT tracers. In contrast to SPECT, PET offers a higher spatial resolution and, owing to the (68)Ge/(68)Ga generator, an analog to the established (99m)Tc generator exists. Complexation of Ga(III) requires the use of chelators...
May 18, 2017: Pharmaceuticals
https://www.readbyqxmd.com/read/28518105/murine-lymphocyte-labeling-by-64cu-antibody-receptor-targeting-for-in-vivo-cell-trafficking-by-pet-ct
#6
Sabrina H L Hoffmann, Andreas Maurer, Dorothea I Reck, Gerald Reischl, Bernd J Pichler, Manfred Kneilling, Christoph M Griessinger
This protocol illustrates the production of (64)Cu and the chelator conjugation/radiolabeling of a monoclonal antibody (mAb) followed by murine lymphocyte cell culture and (64)Cu-antibody receptor targeting of the cells. In vitro evaluation of the radiolabel and non-invasive in vivo cell tracking in an animal model of an airway delayed-type hypersensitivity reaction (DTHR) by PET/CT are described. In detail, the conjugation of a mAb with the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is shown...
April 29, 2017: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/28507297/a-one-pot-three-component-double-click-method-for-synthesis-of-67-cu-labeled-biomolecular-radiotherapeutics
#7
Katsumasa Fujiki, Shinya Yano, Takeshi Ito, Yuki Kumagai, Yoshinori Murakami, Osamu Kamigaito, Hiromitsu Haba, Katsunori Tanaka
A one-pot three-component double-click process for preparing tumor-targeting agents for cancer radiotherapy is described here. By utilizing DOTA (or NOTA) containing tetrazines and the TCO-substituted aldehyde, the two click reactions, the tetrazine ligation (an inverse electron-demand Diels-Alder cycloaddition) and the RIKEN click (a rapid 6π-azaelectrocyclization), could simultaneously proceed under mild conditions to afford covalent attachment of the metal chelator DOTA or NOTA to biomolecules such as to albumin and anti-IGSF4 antibody without altering their activities...
May 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28505219/64cu-dota-trastuzumab-pet-imaging-for-her2-specific-primary-lesions-of-breast-cancer
#8
S Sasada, H Kurihara, T Kinoshita, M Yoshida, N Honda, T Shimoi, A Shimomura, M Yunokawa, K Yonemori, C Shimizu, A Hamada, Y Kanayama, Y Watanabe, Y Fujiwara, K Tamura
No abstract text is available yet for this article.
May 15, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28505112/optimizing-the-readout-of-lanthanide-dota-complexes-for-the-detection-of-ligand-bound-copper-i
#9
Jill R Hanna, Christopher Allan, Charlotte Lawrence, Odile Meyer, Neil D Wilson, Alison N Hulme
The CuAAC 'click' reaction was used to couple alkyne-functionalized lanthanide-DOTA complexes to a range of fluorescent antennae. Screening of the antenna components was aided by comparison of the luminescent output of the resultant sensors using data normalized to account for reaction conversion as assessed by IR. A maximum 82-fold enhanced signal:background luminescence output was achieved using a Eu(III)-DOTA complex coupled to a coumarin-azide, in a reaction which is specific to the presence of copper(I)...
May 14, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28491052/receptor-mediated-melanoma-targeting-with-radiolabeled-%C3%AE-melanocyte-stimulating-hormone-relevance-of-the-net-charge-of-the-ligand
#10
Jean-Philippe Bapst, Alex N Eberle
A majority of melanotic and amelanotic melanomas overexpress melanocortin type 1 receptors (MC1Rs) for α-melanocyte-stimulating hormone. Radiolabeled linear or cyclic analogs of α-MSH have a great potential as diagnostic or therapeutic tools for the management of malignant melanoma. Compounds such as [(111)In]DOTA-NAP-amide exhibit high affinity for the MC1R in vitro, good tumor uptake in vivo, but they may suffer from relatively high kidney uptake and retention in vivo. We have shown previously that the introduction of negative charges into radiolabeled DOTA-NAP-amide peptide analogs may enhance their excretion and reduce kidney retention...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/28474140/comparison-of-psma-hbed-and-psma-i-t-as-diagnostic-agents-in-prostate-carcinoma
#11
Michael McCarthy, Tiffany Langton, Divesh Kumar, Andrew Campbell
PURPOSE: Gallium(68)-labelled prostate-specific membrane antigen (PSMA) radiopharmaceuticals can be used to detect prostate cancer (PCa) cells due the their over expression of PSMA. The (68)Ga HBED-PSMA (PSMA-HBED) ligand has been most widely used and can be considered the current gold standard agent. Further PSMA ligands based on the DOTAGA and DOTA conjugates have more recently been developed. These agents (PSMA-I&T and PSMA-617) have potential theranostic capabilities as they can be conjugated with therapeutic radioisotopes...
May 4, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28471845/early-efficacy-of-and-toxicity-from-lutetium-177-dotatate-treatment-in-patients-with-progressive-metastatic-net
#12
Deborah Pencharz, Martin Walker, Mehmet Yalchin, Ann-Marie Quigley, Martyn Caplin, Christos Toumpanakis, Shaunak Navalkissoor
OBJECTIVE: Lutetium-177 DOTA-D-Phe1-Tyr3-octreotide (Lu-DOTATATE) is a treatment option for patients with well-differentiated metastatic neuroendocrine tumours. Our centre started administering this therapy in 2012. The aim of this study was therefore to analyse the first cohort of patients treated with Lu-DOTATATE to determine its early efficacy and toxicity. PATIENTS AND METHODS: We retrospectively analysed patient, tumour and treatment characteristics, end-of-treatment outcome, time to progression and toxicity in 79 consecutive patients treated with Lu-DOTATATE who had progressive NET according to Response Evaluation Criteria in Solid Tumours criteria...
May 3, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28468949/identification-of-a-novel-the-itg%C3%AE-v%C3%AE-6-binding-peptide-using-protein-separation-and-phage-display
#13
Uwe Haberkorn, Annette Altmann, Max Sauter, Saskia Roesch, Walter Mier, Rolf Warta, Juergen Debus, Gerhard Dyckhoff, Christel Herold-Mende
PURPOSE: Targeted therapies are regarded as promising approaches to increase 5-year survival rate of head and neck squamous cell carcinoma (HNSCC) patients. EXPERIMENTAL DESIGN: For the selection of carcinoma-specific peptides membrane proteome of HNO97 tumor cells fractionated by the ProteomeLab™ PF2D system and corresponding HNO97 cells were deployed for an alternating biopanning using a sunflower trypsin inhibitor1-based phage display (SFTI8Ph) library. Stability, binding properties and affinity of novel candidates were assessed in vitro using radio-HPLC, binding experiments and surface plasmon resonance assay (SPR), respectively...
May 3, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28466861/the-cam-cancer-xenograft-as-a-model-for-initial-evaluation-of-mr-labelled-compounds
#14
Zhi Zuo, Tatiana Syrovets, Yuzhou Wu, Susanne Hafner, Ina Vernikouskaya, Weina Liu, Genshan Ma, Tanja Weil, Thomas Simmet, Volker Rasche
Non-invasive assessment of the biodistribution is of great importance during the development of new pharmaceutical compounds. In this contribution, the applicability of in ovo MRI for monitoring the biodistribution of MR contrast agent-labelled compounds was investigated in mamaria carcinomas xentotransplanted on the chorioallantoic membrane (CAM) exemplarily for Gd-DOTA and cHSA-PEO (2000)16-Gd after systemic injection of the compounds into a chorioallantoic capillary vein. MRI was performed directly prior and 30 min, 3 h, 5 h, 20 h, and 40 h after injection of the compound...
May 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28462171/multiple-recurrent-paraganglioma-in-a-pediatric-patient-with-germline-sdh-b-mutation
#15
Aidan McGowan, Julie Y An, Sally Tanakchi, Mahir Maruf, Akhil Muthigi, Arvin George, Daniel Su, Maria J Merino, W Marston Linehan, Shawna L Boyle, Adam R Metwalli
Magnetic Resonance Imaging (MRI) and fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) are recognized approaches for locating paragangliomas. Recently, gallium-68 DOTA-octreotate (DOTATATE) scans have shown promise detecting neuroendocrine tumors missed by FDG-PET and MRI. 13-year-old male with SDH-B mutation presented with symptoms of paraganglioma and elevated catecholamines. MRI did not demonstrate the T2 hyper intense signal typical of paraganglioma and pheochromocytoma; FDG-PET scan did not reveal increased foci of uptake...
July 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28455851/fragmentation-behavior-of-dota-complexes-under-different-activation-conditions
#16
Sebastian Beck, Sabrina Trog, Sarah Knizia, Michael W Linscheid
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is a macrocycle that is able to complexate a large variety of metals. The stability of these metal complexes is generally very high. This has led to the use of these complexes in medical applications, e.g. magnetic resonance imaging. Here, we have investigated the fragmentation behavior of a number of DOTA-metal complexes under collision-induced dissociation (CID), infrared-multiphoton dissociation (IRMPD) and higher-energy collisional dissociation (HCD) activation conditions...
April 28, 2017: Journal of Mass Spectrometry: JMS
https://www.readbyqxmd.com/read/28451334/zirconium-tetraazamacrocycle-complexes-display-extraordinary-stability-and-provide-a-new-strategy-for-zirconium-89-based-radiopharmaceutical-development
#17
Darpan N Pandya, Nikunj Bhatt, Hong Yuan, Cynthia S Day, Brandie M Ehrmann, Marcus Wright, Ulrich Bierbach, Thaddeus J Wadas
We report our initial investigations into the use of tetraazamacrocycles as zirconium-89 chelators. We describe the synthesis and complete characterization of several Zr tetraazamacrocycle complexes, and definitively describe the first crystal structure of zirconium 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (Zr-DOTA) using single crystal X-ray diffraction analysis. After evaluating several radioactive analogs, we found that (89)Zr-DOTA is superior to (89)Zr-DFO, the only (89)Zr-complex to be used clinically in (89)Zr-radiopharmaceutical applications...
March 1, 2017: Chemical Science
https://www.readbyqxmd.com/read/28450564/diagnostic-pet-imaging-of-mammary-microcalcifications-using-64-cu-dota-alendronate-in-a-rat-model-of-breast-cancer
#18
Bradley J Ahrens, Lin Li, Alexandra K Ciminera, Junie Chea, Erasmus Poku, James R Bading, Michael R Weist, Marcia M Miller, David M Colcher, John E Shively
The development of improved breast cancer screening methods is hindered by a lack of cancer specific imaging agents and effective small animal models to test them. The purpose of this study was to evaluate (64)Cu-DOTA-alendronate as a mammary microcalcification targeting PET imaging agent, using an ideal rat model. Our long-term goal is to develop (64)Cu-DOTA-alendronate for the detection and non-invasive differentiation of malignant versus benign breast tumors with PET. Methods: DOTA-alendronate was synthesized, radiolabeled with (64)Cu and administered to normal or tumor-bearing aged, female, retired breeder, Sprague Dawley rats for PET imaging...
April 27, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28450563/sstr-mediated-breast-cancer-imaging-is-there-a-role-for-radiolabeled-sstr-antagonists
#19
Simone U Dalm, Joost Haeck, Gabriela N Doeswijk, Erik de Blois, Marion de Jong, Carolien van Deurzen
INTRODUCTION: Recent studies showed enhanced tumor targeting by novel somatostatin receptor (SSTR) antagonists compared to clinically widely used agonists. However, these results have mostly been obtained in neuroendocrine tumors and only limited data is available for cancer types with lower SSTR expression, including breast cancer (BC). To date, only two studies reported higher binding of the antagonist versus the agonist in BC, but in both studies a limited number of cases were evaluated. In this pre-clinical study, we further investigated whether the application of a SSTR antagonist could improve SSTR-mediated BC imaging in a large panel of BC specimens...
April 27, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28450554/biodistribution-pharmacokinetics-and-dosimetry-of-177-lu-90-y-and-111-in-labeled-somatostatin-receptor-antagonist-ops201-in-comparison-to-the-agonist-177-lu-dota-tate-the-mass-effect
#20
Guillaume Pierre Nicolas, Rosalba Mansi, Lisa McDougall, Jens Kaufmann, Hakim Bouterfa, Damian Wild, Melpomeni Fani
Radiolabeled somatostatin receptor (sstr) antagonists have shown in vivo higher uptake in sstr-expressing tumors than agonists. In this pre-clinical study the sstr2-antagonist OPS201 (DOTA-JR11; DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2]) labeled with (177)Lu, (90)Y and (111)In was compared with the sstr2-agonist (177)Lu-DOTA-TATE. Methods: Biodistribution, pharmacokinetics, single-photon emission computed tomography/computed tomography (SPECT/CT) and dosimetry studies were performed to assess the bioequivalence of all radiotracers...
April 27, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
90769
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"